Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies February 5, 2026
FDA rejects AZ’s subQ Saphnelo, but company expects quick turnaround for new approval decision February 3, 2026
Rheumatologists view CAR T-cell therapy as ‘revolutionary,’ but cost, safety temper enthusiasm January 23, 2026
Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights January 20, 2026
